GlassScriptPhysician profile
Kevin T Budke
NPI 1154378461
$510.32
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $234 · 2020: $77.88 · 2021: $86.63 · 2022: $112.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $78.08 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $68.77 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.69 | 2019 | |
| Cranial Technologies, INC | $34.16 | 2019-2021 | |
| Amgen INC. | $27.06 | 2019 | |
| Glaxosmithkline, LLC. | $24.92 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $24.78 | 2019-2020 | |
| Kaleo, INC. | $23.86 | 2019-2022 | |
| Lilly USA, LLC | $22.46 | 2019-2020 | |
| Amarin Pharma, INC. | $17.89 | 2020 | |
| Corium, LLC | $17.25 | 2022 | |
| Astellas Pharma US INC | $17.19 | 2019 | |
| Novartis Pharmaceuticals Corporation | $16.48 | 2019 | |
| Neos Therapeutics, LP | $15.61 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.48 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $14.70 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.39 | 2019 | |
| Shire North American Group INC | $12.25 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.45 | 2019 | |
| Sanofi Pasteur INC. | $10.85 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Budke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.